Director Dealing and Issue of Equity

RNS Number : 1108T

Avacta Group PLC

09 October 2017

 

09 October 2017

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Director Dealing and Issue of Equity

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that application has been made for 5,311 new ordinary shares of 10p each (the "New Ordinary Shares") to be admitted to trading on AIM on 16 October 2017 ("Admission").

The New Ordinary Shares have been allotted pursuant to the purchase by Michael Albin, Non-Executive Director of the Company, of New Ordinary Shares in accordance with the terms set out in the Company's announcement of 23 February 2016.

Following Admission, the total number of ordinary shares with voting rights in issue will be 68,403,244. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking WG Partners David Wilson Nigel Barnes Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Media Enquiries FTI Consulting Simon Conway / Natalie Garland-Collins	Tel: [phone] [e-mail]

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michael Albin
2.	Reason for the Notification
a)	Position/status	Non - Executive Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Avacta Group Plc
b)	LEI	2138009U3EG31OPMGH36
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 10p
	Identification code	GB00BYYW9G87
b)	Nature of the transaction	As set out in the Company's announcement of 23 February 2016, on 22 February 2016 Mr Albin entered into a binding commitment to purchase new Avacta shares amounting to 50% of his contractual non-executive director fee per quarter and the New Ordinary Shares represent his investment for the period of 1 July 2017 to 30 September 2017.
c)	Price(s) and volume(s)	Price(s) Volume(s) 70.6 pence 5,311
d)	Aggregated information: ·      Aggregated volume ·      Price	See above
e)	Date of the transaction	9 October 2017
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

MSCOKCDPQBDDCKK